These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22847201)

  • 1. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.
    Buzková H; Pechandová K; Danzig V; Vareka T; Perlik F; Zak A; Slanar O
    Med Sci Monit; 2012 Aug; 18(8):CR512-517. PubMed ID: 22847201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
    Couvert P; Giral P; Dejager S; Gu J; Huby T; Chapman MJ; Bruckert E; Carrié A
    Pharmacogenomics; 2008 Sep; 9(9):1217-27. PubMed ID: 18781850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.
    Ballantyne CM; Pazzucconi F; Pintó X; Reckless JP; Stein E; McKenney J; Bortolini M; Chiang YT
    Clin Ther; 2001 Feb; 23(2):177-92. PubMed ID: 11293552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
    Isaacsohn JL; LaSalle J; Chao G; Gonasun L
    Clin Ther; 2003 Mar; 25(3):904-18. PubMed ID: 12852707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
    Goldberg RB; Roth D
    Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.
    Miroševic Skvrce N; Božina N; Zibar L; Barišic I; Pejnovic L; Macolic Šarinic V
    Pharmacogenomics; 2013 Sep; 14(12):1419-31. PubMed ID: 24024895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.
    Kim MJ; Nafziger AN; Kashuba AD; Kirchheiner J; Bauer S; Gaedigk A; Bertino JS
    Eur J Clin Pharmacol; 2006 Jun; 62(6):431-6. PubMed ID: 16758259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
    Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
    Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
    Wu JC; Nafziger AN; Bertino JS; Ma JD
    Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
    Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
    Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
    Sprecher DL; Abrams J; Allen JW; Keane WF; Chrysant SG; Ginsberg H; Fischer JJ; Johnson BF; Theroux P; Jokubaitis L
    Ann Intern Med; 1994 Apr; 120(7):537-43. PubMed ID: 8093139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group.
    Jacotot B; Banga JD; Waite R; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):41A-46A. PubMed ID: 7604796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
    Olsson AG; Pauciullo P; Soska V; Luley C; Pieters RE; Broda G; Palacios B;
    Clin Ther; 2001 Jan; 23(1):45-61. PubMed ID: 11219479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.